68Ga-RM2 PET and 68Ga-PSMA11 PET done 1-12 days (mean±SD: 3.7±3.8) apart identified 23 and 21 intraprostatic lesions, respectively, as well as 4 and 5 pelvic lymph nodes, respectively. Non-congruent findings between 68Ga-RM2 PET and 68Ga-PSMA11 PET were recorded in 4/13 ...
[68Ga]Ga-RM2 is a new PET-tracer targeting GRP receptors. It is of importance to predict the patients' outcomes from the initial diagnosis. Here, we aimed to evaluate the value of [18F]Choline and [68Ga]Ga-RM2 PET/computed tomography (CT) for the prediction of the recurrence in ...
Conclusion At least in our small and heterogeneous patient population, (68) Ga-RM2 showed no clinically relevant, additional benefit compared to (68) Ga-PSMA-11 PET.Hoberueck, SebastianMichler, EnricoWunderlich, GerdLoeck, SteffenHoelscher, TobiasFroehner, MichaelBraune, AnjaPlatzek, IvanSeppelt, ...
[68Ga]Ga-RM2 is a well-established radiotracer for PET imaging of GRPr, and [177Lu]Lu-RM2 has been proposed as a therapeutic alternative for patients with heterogeneous and/or low expression of PSMA. In this study, we aimed to evaluate the expression of GRPr and ...
[ 68 Ga]Ga-RM2 uptake was significantly reduced on post-NAC PET in all primary tumors (mean SUVmax 2.3±0.8, -79±11%; p=0.0125; mean SUVpeak 1.6±0.4, -79±10%; p=0.0096). Residual tumor size in resected specimens correlated well with SUVmax (r=0.91, p=0.0057) and SUVpeak (...
Before HIFU, 68Ga-PSMA11 identified all target tumors, whereas 68Ga-RM2 PET/MRI missed 2 tumors. After HIFU, 68Ga-RM2 and 68Ga-PSMA11 PET/MRI both identified clinically significant residual disease in 1 patient. Three significant ipsilateral recurrent lesions were id...
Ga68RM2Aim Ga-RM2 is a bombesin (BBN) analog that targets the gastrin releasing peptide receptors (GRPR) overexpressed in many cancer cells, including prostate cancer (PC). It has been reported to successfully detect primary and recurrent PC. Here, we describe the distribution and range of ...
Ga-68-labeled prostate-specific membrane antigen inhibitors and Ga-68-labeled gastrin-releasing peptide receptor antagonists showed interesting results for staging biochemically recurrent prostate cancer. In this case, Ga-68-prostate-specific membrane antigen-617 PET/CT, Ga-68-RM2 PET/CT, and F-18...
Methods: Eight patients with histologically proven primary prostate cancer underwent two positron emission tomography with computer tomography scans, [68Ga]Ga-RM2-PET/CT (RM2-PET) and [68Ga]Ga-PSMA-11-PET/CT (PSMA-PET), prior to radical prostatectomy. RM2-PET data were correlated voxel-wise...
Moreover, the synergic use of both 68Ga-PSMA and 68Ga-DOTA-RM2 that highlight different metabolic aspects of the tumour, might further improve the characterization of PCa in the staging phase. The aim of this work is to study the performances of 68Ga-PSMA, 68Ga-DOTA-RM2 PET and MRI ...